Education:

• 1975 - 1979 Cornell University, College of Agricultural and Life Sciences, Ithaca, New York - BS, Biological Sciences
• 1981 - 1983 Columbia University, College of General Studies, New York, New York
• 1983 - 1984 SUNY - Downstate Medical School, Brooklyn, New York
• 1984 - 1987 Cornell University Medical College, New York, New York - MD

Post Graduate Training:

• 1987 - 1988 Internship, Internal Medicine, Lenox Hill Hospital, New York, New York
• 1988 - 1991 Residency, Department of Neurology, University Hospitals of Cleveland, Cleveland, Ohio
• 1991 - 1993 Fellowship, Alzheimer Disease/ Geriatric Neurology, University Hospitals of Cleveland, Cleveland, Ohio

Licensure or Certification:

• November 1992 - Board Certification, American Board of Psychiatry and Neurology
• 1989 - Present, Medical License - Ohio 35 - 05 - 8111

Associations:

• 1989 - Present, American Academy of Neurology
• 1991 - Present, Behavioral Neurology Society
• 1992 - Present, Society for Neuroscience
• 1992 - Present, International Brain Research Organization
• 1995 - Present, International Society for the Investigation of Stress
• 1993 - Present, Professional advisory board, Alzheimer Association - Cleveland Chapter
• 1994 - Present, Chairman, Research Review Subcommittee, Alzheimer Association - Cleveland Chapter

Affiliations:

• Medical Director, Clarebridge of Bainbridge, Bainbridge, Ohio 1999 - Present
  
• Assistant Professor of Neurology
  Case Western Reserve University School of Medicine, Cleveland, Ohio, 1994 - Present
• Neurology Practice
  Alan J. Lerner, MD (sole proprietorship) Cleveland, Ohio and Beechwood, Ohio 1993 - 1997
• Director, Division of Neurology
  Department of Medicine - Columbia, Saint Luke's Medical Center, Cleveland, Ohio 1993 - 1997
• Consultant - Clinic Drug Trials
  Alzheimer Center, University Hospitals of Cleveland, Case Western Reverve University, 1993 - 1997
• Guest Lecturer
  Ohio College of Podiatric Medicine, Cleveland, Ohio, 1992 - Present

Partial List of Publications:

• Lerner AJ: Alzheimer's disease in males: Endocrine aspects and prospects. Journal of Clinical Endocrinology and Metabolism, 1999 (in press).
• Lerner AJ: Women and Alzheimer's disease. Journal of Clinical Endocrinology and Metabolism, 1999 84(6): 1830 - 1834.
• Hemingway-Eltomey JM, Lerner AJ: Adverse effects of donepezil in treating Down's syndrome associated Alzheimer's disease. The American Journal of Psychiatry, 1999 156(9):1470.
• Friedland RP, Farrer LA, Cupples LA, Lerner AJ, and the MIRAGE study group. Smoking and duration of illness in Alzheimer's disease. Research letter, The Lancet, 1998.
• Lerner AJ. Drug Evaluation: Ebiratide. Current Research in Alzheimer's Disease, 3 (4),1998.
• Hedera P, Wu D, Collins S, Lewin JS, Miller D, Lerner AJ, Klein S, Friedland RP. Sex and Electroencephalographic after photic stimulation predict signal changes in the visual cortex detected by functional MR images. American Journal of Neuroradiology, 19: 853 - 857, 1998.
• Geldmacher DS, Lerner AJ, Voci JM, Noelker EA, SompleCL, Whitehouse PJ. Treating functional decline in Down's syndrome using selective serotonin reuptake inhibitor drugs. Journal of Geriatric Psychiatry and Neurology, 1997, 10:99 - 104.
• Lerner AJ, Koss E, Bebanne SM, Rowland DY, Smyth KA, Friedland RP: Interactions of smoking history with estrogen replacement therapy as protective factors for Alzheimer's disease. Research Letter, Lancet, February 8, 1997, p. 403 - 404.
• Clark C, Ewbank D, Lerner A, Doody R, Henderson VW, Panisset M, Morris JC, Fillenbaum G, Heyman A and the CERAD collaborators. The Relationship between Extrapyramidal Signs and Cognitive Performance in Patients with Alzheimer's Disease . Neurology, 1997; 49: 70-75.
• Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP. Delirium in Alzheimer's disease. Alzheimer's Disease and Associated Disorders, 1997; 11:16 - 20.
• Hedera P, Lai S, Lewin JS, Haacke EM, Wu D, Lerner AJ, Friedland RP. Assessment of cerebral blood flow reserve using functional magnetic resonance imaging. Journal of Magnetic Resonance Imaging, 1996, 6:718 - 725.
• Hedera P, Wu D, Lewin JS, Miller D, Lerner AJ, Friedland RP. Temporal patterns of uncoupling between oxidative metabolism and regional cerebral blood flow demonstrated by functional magnetic resonance imaging. Investigative Radiology, 1995; 30:625 - 633.
• Lerner AJ, Koss E, Patterson MB, Ownby RL, Hedera P, Friedland RP, Whitehouse PJ. Concomitants of visual hallucinations in Alzheimer's disease. Parkinson/Alzheimer Digest, April 1995.
• Hedera P, Lerner AJ, Castellani R, Friedland RP. Concurrence of Alzheimer's disease, Parkinson's disease, diffuse Lewy body disease, and Amyotrophic Lateral Sclerosis. Journal of the Neurological Sciences, 1995; 128:219 -224.
• Hedera P, Lai S, Haacke EM, Lerner AJ, Hopkins AL, Lewin JS, Friedland RP. Abnormal connectivity of the visual pathways in human albinos demonstrated by susceptibility sensitized magnetic resonance imaging. Neurology 1994; 44:1921 - 1926.
• Hedera P, Cohen ML, Lerner AJ, Friedland RP. Dementia preceding motor symptoms in Parkinson's disease: A case study. Neuropsychiatry, Neuropsychology, and Behavioral Neurology, 1994; 7:67 - 72.
• Lerner AJ, Koss E, Patterson MB, Ownby RL, Hedera P, Friedland RP, Whitehouse PJ. Concomitants of visual hallucinations in Alzheimer's disease. Neurology 1994; 44:523 - 527.

Grants:

• Co-Investigator
  An open-label study to evaluate the safety and efficacy of 1.5 mg. b.i.d. (3 mg/day) through 6 mg. b.i.d. (12 mg/day) of ExelonO in patients with mild to severe probable Alzheimer's disease in the community setting (Novartis, ENAB-356) 1997 - Present
• Principal Investigator
  A multicenter placebo-controlled trial of Melatonin for sleep disturbance in Alzheimer's Disease (NIA/Clinical Study Group Consortium) 1997 - Present
• Principal Investigator
  Efficacy and safety of 6, 12, 24 and 36 mg orally three times daily and 36 mg orally twice daily talsalclidine for 12 weeks in a double blind, randomized, placebo-controlled parallel group comparison in patients with mild to moderate dementia of the Alzheimer's type (phase II, Novartis) 1998.
• Principal Investigator
  A multicenter double-blind, placebo controlled study of estrogen replacement therapy in patients with mild to moderate Alzheimer's disease (IND 48114, NIA / Clinical study group consortium). (July 1998 - February 1999)
• Principal Investigator
  A randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of Vitamin E and Donepezil HCl (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD). Clinical Study Group, 1998 - Present
• Principal Investigator
  A twenty-four-week, multicenter, parallel-group, double-blind, placebo-controlled study of the efficacy, tolerability and safety of estrogen in the treatment of Alzheimer's disease in outpatient women treated with Donepezil (Pfizer Inc, E-0401) 1998 - Present.